Dr. Cofield reported that she has received consulting fees from Teva Neuroscience and GlaxoSmithKline, among others. Biogen Idec funded the analysis of data for this study.
On Twitter @whitneymcknight
Conference Coverage
Switching from natalizumab to fingolimod or injectables increased MS disability
Publish date: June 1, 2014
AT THE CMSC/ACTRIMS ANNUAL MEETING